The first Cuban-American joint venture in the Biotechnology sector was established

The constitution as a new user of the Mariel Special Development Zone, of the first Cuban-American Joint Venture in September 2018, Innovative Immunotherapy Alliance, SA, represents a milestone in relations between both countries and confirms the strength of Cuban Biotechnology and its international positioning.

The association between the Center for Molecular Immunology (CIM) of Cuba and the American Roswell Park Cancer Center, of the State of New York, and its affiliates, will focus on the research, development and commercialization of innovative Cuban medicines for the benefit of cancer patients in the United States, starting with CIMAvax-EGF and three other innovative immunotherapies

.